Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

...ay is being fully funded by an external grant provided by a private organization. KRX-0401 is a novel, oral, anticancer agent that modulates akt and several other important signal transduction pathways. Keryx is currently in the process of finalizing late-stage protocols for Perifosine in the t...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

...ancer and aberrant PI3K pathway activity is observed with high frequency in a variety of tumor types. PI3K signaling through its downstream effectors akt and mTOR is also known to promote tumor cell survival, proliferation, and growth. Dysregulation of PI3K signaling is also thought to contribute resis...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

...ancer and aberrant PI3K pathway activity is observed with high frequency in a variety of tumor types. PI3K signaling through its downstream effectors akt and mTOR is also known to promote tumor cell survival, proliferation, and growth. Notably, dysregulation of PI3K signaling is thought to contribute t...

FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway

...ess pathway, that received FDA acceptance of its IND in the second quarter of 2009. AR-42, an orally available, targeted inhibitor of the Pan-DAC and akt pathways received FDA acceptance of its IND in the first quarter of 2009. For more information on Arno please visit www.arnothera.com . ...

Bionovo Announces First Quarter 2009 Highlights and Financial Results

...as an active compound of BN108 that is responsible for BN108's selective cytotoxicity. BN108 and TspA3 induce apoptosis through rapid inactivation of akt and mTOR kinases in breast cancer cells but not in normal cells. Two additional members joined Bionovo's Scientific Advisory Board, Jan-Ake G...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

...inal Results of a Phase II Trial of the Novel Oral akt Inhibitor Perifosine in Relapsed and/or Refractory...st-in-class, oral anti-cancer agent that modulates akt and a number of other key signal transduction path...n and cell survival. The effects of perifosine on akt are of particular interest because of the importan...

SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines

... In vitro inhibition of the PI3K/AKT/mTOR pathway by SF1126 was demonstrated to impede the ability of angiogenic stimulants VEGF and Bv8 to activate akt in a dose dependant manner in two cancer cell lines (786-0 -- renal cell and PC3 prostate) and one endothelial cell line (HBEC -- human brain endothel...

Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.

...ressive form of brain cancer. AR-12 is a PDK-1 inhibitor that targets the akt pathway while also possessing activity in the endoplasmic reticulum (ER) st...arceva(R) and tamoxifen. AR-42 is a targeted inhibitor of the Pan-DAC and akt pathways. In preclinical studies, AR-42 has demonstrated greater potency an...

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

... Abstract 8546: A PHASE II TRIAL OF THE NOVEL ORAL akt INHIBITOR PERIFOSINE (KRX-0401) IN RELAPSED AND/OR...st-in-class, oral anti-cancer agent that modulates akt and a number of other key signal transduction path...on and cell survival. The effects of perifosine on akt are of particular interest because of the importan...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

... Abstract 8546: A Phase 2 trial of the novel oral akt inhibitor perifosine in relapsed and/or refractory...CC): Abrogation of rapamycin-mediated induction of akt phosphorylation by perifosine. Investigators: W....st-in-class, oral anti-cancer agent that modulates akt and a number of other key signal transduction path...

Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology

...ber of different signal transduction pathways including Akt, MAPK, and JNK. akt isoforms have been found to be overexpressed in renal, breast, prostate, an...her features associated with poor prognosis. The effects of perifosine on akt are of particular interest because of 1) the importance of this pathway in ...

Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium

...n oral presentation entitled "PERIFOSINE: AN ORAL, akt INHIBITOR WITH CLINICAL ACTIVITY IN ADVANCED RENAL...ransduction pathways including Akt, MAPK, and JNK. akt isoforms have been found to be overexpressed in re...with poor prognosis. The effects of perifosine on akt are of particular interest because of 1) the impor...

Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma

...rst-in-class, oral anticancer agent that modulates akt and a number of other key signal transduction path...ation and cell survival. High levels of activated akt (pAkt) are seen frequently in many types of cancer...e newer biologicals. The effects of perifosine on akt are of particular interest because of 1) the impor...

EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model

...m.com/cgi-bin/prnh/20010620/ENMDLOGO ) Activation of the oncogenic kinase akt and the mTOR pathway are known to be adverse prognostic factors and contrib... vitro were shown to have marked sensitivity to MKC-1. MKC-1 inhibited both akt and mTOR pathway activation in vitro, and was further evaluated in a precli...

Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)

...ibody to target IGF-1R (insulin-like growth factor receptor), in patients with solid tumors. IGF-1 is one of the most potent natural activators of the akt and MAPK signaling pathways, which promote cell growth and cell survival. The IGF-1R pathway has also been shown to have an important role in mediatin...

VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)

...marily for oncology and infectious diseases. VioQuest has three targeted drug candidates in clinical development: VQD-002 which inhibits activation of akt that is seen at abnormally high levels in breast, ovarian, colorectal, pancreatic, and hematologic cancers; Lenocta(TM), an inhibitor of specific prot...

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

...cit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical tria...

Callisto Reports on Second-Quarter 2007 Milestones

...cit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical tria...

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

...cit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical tria...

Immunosuppressant Drug Prevents Tobacco Induced Lung Cancer in Mice

...wn as NNK, stimulate the activity of two proteins, akt and mTOR, in normal cells that line the airways in...ous. In addition, clinical studies have shown that akt is activated in the majority of pre-cancerous lesi...or with small tumors. These studies suggested that akt and mTOR are important elements in the formation a...

Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

...cit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical tria...

Biomira Selects PX-866 as Clinical Development Candidate and Presents Promising Preclinical Data at AACR

...on the status of PTEN in the cell lines, with PTEN-negative cells showing greater sensitivity to PX-866. Treatment with PX-866 inhibited activation of akt and other downstream targets of PI3K. A dose-dependent increase in autophagy, a type of programmed cell death, was observed and PX-866 also inhibited ...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51

...atment alone in the inhibition of cell proliferation and phosphorylation of akt in EGF and PDGF pathways. Moreover, in combination with Tarceva, MP470 inhibited akt phosphorylation in LNCaP prostate cells. Finally, the MP470/Tarceva treatme...

EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers

...lso shown to inhibit PI3-Kinase and mTOR pathways by inducing a dose-dependent reduction in the levels of the activated forms of the oncogenic kinases akt and p70S6K. These signaling pathways are strongly linked to cancer proliferation and survival. Additionally, MKC-1 showed enhanced activity with cyt...

VioQuest Pharmaceuticals Announces Data Presentation for Its Akt Inhibitor VQD-002, at American Association for Cancer Research Annual Meeting

...ee these findings presented at AACR for our direct akt inhibitor, VQD-002, in combination with another ta...ns provided at AACR, showing the importance of the akt pathway in human cancer," said Dr. Edward Bradley,...udies suggest that combined inhibition of Cdk9 and akt can be effective in treating metastatic prostate c...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

...sphorylation of MET following administration of XL880. These decreases resulted in predicted downstream effects, including reduction of phosphorylated akt levels and markedly increased tumor cell death. These effects were not observed in control samples of normal tissue obtained from the same patients. P...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

...llows: Perifosine, an Oral Bioactive Novel akt Inhibitor, Induces In Vitro and In Vivo Anti...itute, Boston, MA Combination of the akt Inhibitor Perifosine with the HSP90 Inhibitor 17- ...rst-in-class, oral anticancer agent that modulates akt and a number of other key signal transduction path...